Tiagabine for complex partial seizures: A randomized, add-on, dose- response trial

Archives of Neurology

Volumn 55, Issue 1, 1998, Pages 56-62

  Uthman, Basim M ^a   Rowan, A James ^b   Ahmann, Peter A ^b   Leppik, Ilo E ^b   Schachter, Steven C ^b   Sommerville, Kenneth W ^b   Shu, Vincent ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREMOR; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NIPECOTIC ACIDS; TREATMENT OUTCOME;

EID: 0031886001     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.1.56     Document Type: Article

References (11)

1. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl) but-3-en-1-yl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier, J Neurochem. 1990;54:639-647.
2. Suzdak P, Jansen J. A review of the preclinical pharmacology of tiagabine, a potent and selective anticonvulsant GABA uptake inhibitor, Epilepsia. 1995;36:612-626.
3. Gustavsan LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor in healthy subjects after single and multiple doses. Epilepsia. 1995;36:605-611.
4. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res. 1995;22:221-226.
5. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial, Epilepsy Res, 1995;21:37-42.
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. COSTART: Coding Symbols for The-saurus of Adverse Reaction Terms. 3rd ed. Springfield Va: National Technical Information Service; 1989.
7. van Eiteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Int Stat. 1960;37:351-361.
8. SAS Institute Inc. SAS-STAT User's Guide, Version 6. 4th ed. Cary. NC: SAS Institute Inc; 1990.
9. Sachdeo R, Leroy R, Krauss G, et al. Safety and efficacy of b.i.d. and q.i.d. dosing with tiagabine HCI versus placebo as adjunctive treatment for partial seizures. Neurology. 1995;45(suppl 4):A202. Abstract.
10. Alto G, Chang S, Sommerville KW. Use of the COSTART term 'thinking abnormal' in a multicenter trial of tiagabine for partial epilepsy. Epilepsia. 1994;35 (suppl 8):116.
11. During M, Mattson RH, Scheyer R, et al. The effect of tiagabine HCI on extracellular GABA levels in the human hippocampus. Epilepsia. 1992;33(suppl 3):83.